This single-center, 400-patient, randomized controlled trial assesses the impact of a patient- and provider-facing EPIC Best Practice Advisory (BPA; alert-based computerized decision support tool) to increase guideline-directed utilization of statin and statin-alternative oral LDL-C lowering therapies in patients with PAD who are not being prescribed LDL-C-lowering therapy.
All patients ≥ 18 years old
Seen in Cardiovascular Medicine Clinic, Primary Care, Podiatry, Vascular Surgery, and Diabetology
Medical history entry, visit diagnosis, or problem list entry of PAD
Not prescribed LDL-C-lowering therapy
Patients taking a statin, ezetimibe, bempedoic acid, a PCSK9 inhibitor, inclisiran or a combination will be excluded
Parallel
Computer Alert
BehavioralOn-screen alert-based decision support raising awareness of need for lipid-lowering therapy in patients with peripheral artery disease
Frequency of prescription of oral LDL-C-lowering therapy
The frequency of prescription of oral LDL-C-lowering therapy will be assessed using a report from the medical record
Change in LDL-C level
Change in LDL-C level will be assessed via the medical record
Frequency of all-cause mortality
The frequency will be assessed using a report from the medical record
Frequency of major adverse cardiovascular events
The frequency of major adverse cardiovascular events (including myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) will be assessed using a report from the medical record
Frequency of major adverse limb events
The frequency of major adverse limb events (including amputation and peripheral artery revascularization) will be assessed using a report from the medical record
Frequency of all-cause hospitalization
The frequency of all-cause hospitalization will be assessed using a report from the medical record
Click on the lead sponsor to view all of their trials.
Brigham and Women's Hospital
Lead sponsor
Esperion Therapeutics, Inc.
Collaborator
